Investing.com — Shares of pharmaceutical agency Eli Lilly & Co (NYSE:) expert a serious drop, as so much as 8.6%, marking most likely probably the most substantial intraday decrease since October.
This hunch was triggered by the company’s preliminary earnings for the fourth quarter, which didn’t meet expectations.
Eli Lilly attributed the disappointing earnings to slower growth of its weight issues and diabetes drugs.
The company anticipates earnings to fluctuate from $58.0 billion to $61.0 billion. However, this estimate falls in want of the projected $58.72 billion.
This textual content was generated with the help of AI and reviewed by an editor. For additional information see our T&C.
rn
rn
Source link ","writer":{"@sort":"Particular person","identify":"Index Investing Information","url":"https://indexinvestingnews.com/writer/projects666/","sameAs":["https://indexinvestingnews.com"]},"articleSection":["Stocks"],"picture":{"@sort":"ImageObject","url":"https://i-invdn-com.investing.com/information/LYNXNPEF150TG_L.jpg","width":0,"top":0},"writer":{"@sort":"Group","identify":"","url":"https://indexinvestingnews.com","emblem":{"@sort":"ImageObject","url":""},"sameAs":["https://www.facebook.com/Index-Investing-News-102075432474739","https://twitter.com/IndexInvesting_"]}}
Source link
